Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: a systematic review
Most of the European Union (EU) and European Economic Area (EEA) is considered a region of very low hepatitis A virus (HAV) endemicity; however, geographical differences exist. We did a systematic review with the aim of describing seroprevalence and susceptibility in the general population or specia...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Carrillo-Santisteve, Paloma [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017transfer abstract |
|---|
| Umfang: |
14 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model - Berhane, S. ELSEVIER, 2016, New York, NY |
|---|---|
| Übergeordnetes Werk: |
volume:17 ; year:2017 ; number:10 ; pages:306-319 ; extent:14 |
| Links: |
|---|
| DOI / URN: |
10.1016/S1473-3099(17)30392-4 |
|---|
| Katalog-ID: |
ELV030304091 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV030304091 | ||
| 003 | DE-627 | ||
| 005 | 20230625181314.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1473-3099(17)30392-4 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000044A.pica |
| 035 | |a (DE-627)ELV030304091 | ||
| 035 | |a (ELSEVIER)S1473-3099(17)30392-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.44 |2 bkl | ||
| 100 | 1 | |a Carrillo-Santisteve, Paloma |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: a systematic review |
| 264 | 1 | |c 2017transfer abstract | |
| 300 | |a 14 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Most of the European Union (EU) and European Economic Area (EEA) is considered a region of very low hepatitis A virus (HAV) endemicity; however, geographical differences exist. We did a systematic review with the aim of describing seroprevalence and susceptibility in the general population or special groups in the EU and EEA. We searched databases and public health national institutes websites for HAV seroprevalence records published between Jan 1, 1975, and June 30, 2014, with no language restrictions. An updated search was done on Aug 10, 2016. We defined seroprevalence profiles (very low, low, and intermediate) as the proportion of the population with age-specific anti-HAV antibodies at age 15 and 30 years, and susceptibility profiles (low, moderate, high, and very high) as the proportion of susceptible individuals at age 30 and 50 years. We included 228 studies from 28 of 31 EU and EEA countries. For the period 2000–14, 24 countries had a very low seroprevalence profile, compared with five in 1975–89. The susceptibility among adults ranged between low and very high and had a geographical gradient, with three countries in the low susceptibility category. Since 1975, EU and EEA countries have shown decreasing seropositivity; however, considerable regional variability exists. The main limitations of this study are that the studies retrieved for analysis might not be representative of all EU and EEA publications about HAV and might have poor national representativeness. A large proportion of EU and EEA residents are now susceptible to HAV infection. Our Review supports the need to reconsider specific prevention and control measures, to further decrease HAV circulation while providing protection against the infection in the EU and EEA, and could be used to inform susceptible travellers visiting EU and EEA countries with different HAV endemicity levels. | ||
| 520 | |a Most of the European Union (EU) and European Economic Area (EEA) is considered a region of very low hepatitis A virus (HAV) endemicity; however, geographical differences exist. We did a systematic review with the aim of describing seroprevalence and susceptibility in the general population or special groups in the EU and EEA. We searched databases and public health national institutes websites for HAV seroprevalence records published between Jan 1, 1975, and June 30, 2014, with no language restrictions. An updated search was done on Aug 10, 2016. We defined seroprevalence profiles (very low, low, and intermediate) as the proportion of the population with age-specific anti-HAV antibodies at age 15 and 30 years, and susceptibility profiles (low, moderate, high, and very high) as the proportion of susceptible individuals at age 30 and 50 years. We included 228 studies from 28 of 31 EU and EEA countries. For the period 2000–14, 24 countries had a very low seroprevalence profile, compared with five in 1975–89. The susceptibility among adults ranged between low and very high and had a geographical gradient, with three countries in the low susceptibility category. Since 1975, EU and EEA countries have shown decreasing seropositivity; however, considerable regional variability exists. The main limitations of this study are that the studies retrieved for analysis might not be representative of all EU and EEA publications about HAV and might have poor national representativeness. A large proportion of EU and EEA residents are now susceptible to HAV infection. Our Review supports the need to reconsider specific prevention and control measures, to further decrease HAV circulation while providing protection against the infection in the EU and EEA, and could be used to inform susceptible travellers visiting EU and EEA countries with different HAV endemicity levels. | ||
| 700 | 1 | |a Tavoschi, Lara |4 oth | |
| 700 | 1 | |a Severi, Ettore |4 oth | |
| 700 | 1 | |a Bonfigli, Sandro |4 oth | |
| 700 | 1 | |a Edelstein, Michael |4 oth | |
| 700 | 1 | |a Byström, Emma |4 oth | |
| 700 | 1 | |a Lopalco, Pierluigi |4 oth | |
| 700 | 1 | |a Alfonsi, Valeria |4 oth | |
| 700 | 1 | |a Chilbek, Roman |4 oth | |
| 700 | 1 | |a Dominguez, Angela |4 oth | |
| 700 | 1 | |a Galanakis, Emmanouil |4 oth | |
| 700 | 1 | |a Janta, Denisa |4 oth | |
| 700 | 1 | |a Kojouharova, Mira |4 oth | |
| 700 | 1 | |a Ott, Jördis J |4 oth | |
| 700 | 1 | |a Nelson, Noele |4 oth | |
| 700 | 1 | |a Papaevangelou, Vassiliki |4 oth | |
| 700 | 1 | |a Shouval, Daniel |4 oth | |
| 700 | 1 | |a Uhnoo, Ingrid |4 oth | |
| 700 | 1 | |a Usonis, Vytautas |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Berhane, S. ELSEVIER |t Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model |d 2016 |g New York, NY |w (DE-627)ELV013808834 |
| 773 | 1 | 8 | |g volume:17 |g year:2017 |g number:10 |g pages:306-319 |g extent:14 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S1473-3099(17)30392-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_26 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_70 | ||
| 936 | b | k | |a 44.44 |j Parasitologie |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 17 |j 2017 |e 10 |h 306-319 |g 14 |y 17.2017, 10, e306-, (14 S.) | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
p c s pcs |
|---|---|
| matchkey_str |
carrillosantistevepalomatavoschilaraseve:2017----:eorvlnenssetbltthpttsiteuoennoaduoenc |
| hierarchy_sort_str |
2017transfer abstract |
| bklnumber |
44.44 |
| publishDate |
2017 |
| allfields |
10.1016/S1473-3099(17)30392-4 doi GBV00000000000044A.pica (DE-627)ELV030304091 (ELSEVIER)S1473-3099(17)30392-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl Carrillo-Santisteve, Paloma verfasserin aut Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: a systematic review 2017transfer abstract 14 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Most of the European Union (EU) and European Economic Area (EEA) is considered a region of very low hepatitis A virus (HAV) endemicity; however, geographical differences exist. We did a systematic review with the aim of describing seroprevalence and susceptibility in the general population or special groups in the EU and EEA. We searched databases and public health national institutes websites for HAV seroprevalence records published between Jan 1, 1975, and June 30, 2014, with no language restrictions. An updated search was done on Aug 10, 2016. We defined seroprevalence profiles (very low, low, and intermediate) as the proportion of the population with age-specific anti-HAV antibodies at age 15 and 30 years, and susceptibility profiles (low, moderate, high, and very high) as the proportion of susceptible individuals at age 30 and 50 years. We included 228 studies from 28 of 31 EU and EEA countries. For the period 2000–14, 24 countries had a very low seroprevalence profile, compared with five in 1975–89. The susceptibility among adults ranged between low and very high and had a geographical gradient, with three countries in the low susceptibility category. Since 1975, EU and EEA countries have shown decreasing seropositivity; however, considerable regional variability exists. The main limitations of this study are that the studies retrieved for analysis might not be representative of all EU and EEA publications about HAV and might have poor national representativeness. A large proportion of EU and EEA residents are now susceptible to HAV infection. Our Review supports the need to reconsider specific prevention and control measures, to further decrease HAV circulation while providing protection against the infection in the EU and EEA, and could be used to inform susceptible travellers visiting EU and EEA countries with different HAV endemicity levels. Most of the European Union (EU) and European Economic Area (EEA) is considered a region of very low hepatitis A virus (HAV) endemicity; however, geographical differences exist. We did a systematic review with the aim of describing seroprevalence and susceptibility in the general population or special groups in the EU and EEA. We searched databases and public health national institutes websites for HAV seroprevalence records published between Jan 1, 1975, and June 30, 2014, with no language restrictions. An updated search was done on Aug 10, 2016. We defined seroprevalence profiles (very low, low, and intermediate) as the proportion of the population with age-specific anti-HAV antibodies at age 15 and 30 years, and susceptibility profiles (low, moderate, high, and very high) as the proportion of susceptible individuals at age 30 and 50 years. We included 228 studies from 28 of 31 EU and EEA countries. For the period 2000–14, 24 countries had a very low seroprevalence profile, compared with five in 1975–89. The susceptibility among adults ranged between low and very high and had a geographical gradient, with three countries in the low susceptibility category. Since 1975, EU and EEA countries have shown decreasing seropositivity; however, considerable regional variability exists. The main limitations of this study are that the studies retrieved for analysis might not be representative of all EU and EEA publications about HAV and might have poor national representativeness. A large proportion of EU and EEA residents are now susceptible to HAV infection. Our Review supports the need to reconsider specific prevention and control measures, to further decrease HAV circulation while providing protection against the infection in the EU and EEA, and could be used to inform susceptible travellers visiting EU and EEA countries with different HAV endemicity levels. Tavoschi, Lara oth Severi, Ettore oth Bonfigli, Sandro oth Edelstein, Michael oth Byström, Emma oth Lopalco, Pierluigi oth Alfonsi, Valeria oth Chilbek, Roman oth Dominguez, Angela oth Galanakis, Emmanouil oth Janta, Denisa oth Kojouharova, Mira oth Ott, Jördis J oth Nelson, Noele oth Papaevangelou, Vassiliki oth Shouval, Daniel oth Uhnoo, Ingrid oth Usonis, Vytautas oth Enthalten in Elsevier Berhane, S. ELSEVIER Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model 2016 New York, NY (DE-627)ELV013808834 volume:17 year:2017 number:10 pages:306-319 extent:14 https://doi.org/10.1016/S1473-3099(17)30392-4 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_26 GBV_ILN_40 GBV_ILN_70 44.44 Parasitologie Medizin VZ AR 17 2017 10 306-319 14 17.2017, 10, e306-, (14 S.) 045F 610 |
| spelling |
10.1016/S1473-3099(17)30392-4 doi GBV00000000000044A.pica (DE-627)ELV030304091 (ELSEVIER)S1473-3099(17)30392-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl Carrillo-Santisteve, Paloma verfasserin aut Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: a systematic review 2017transfer abstract 14 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Most of the European Union (EU) and European Economic Area (EEA) is considered a region of very low hepatitis A virus (HAV) endemicity; however, geographical differences exist. We did a systematic review with the aim of describing seroprevalence and susceptibility in the general population or special groups in the EU and EEA. We searched databases and public health national institutes websites for HAV seroprevalence records published between Jan 1, 1975, and June 30, 2014, with no language restrictions. An updated search was done on Aug 10, 2016. We defined seroprevalence profiles (very low, low, and intermediate) as the proportion of the population with age-specific anti-HAV antibodies at age 15 and 30 years, and susceptibility profiles (low, moderate, high, and very high) as the proportion of susceptible individuals at age 30 and 50 years. We included 228 studies from 28 of 31 EU and EEA countries. For the period 2000–14, 24 countries had a very low seroprevalence profile, compared with five in 1975–89. The susceptibility among adults ranged between low and very high and had a geographical gradient, with three countries in the low susceptibility category. Since 1975, EU and EEA countries have shown decreasing seropositivity; however, considerable regional variability exists. The main limitations of this study are that the studies retrieved for analysis might not be representative of all EU and EEA publications about HAV and might have poor national representativeness. A large proportion of EU and EEA residents are now susceptible to HAV infection. Our Review supports the need to reconsider specific prevention and control measures, to further decrease HAV circulation while providing protection against the infection in the EU and EEA, and could be used to inform susceptible travellers visiting EU and EEA countries with different HAV endemicity levels. Most of the European Union (EU) and European Economic Area (EEA) is considered a region of very low hepatitis A virus (HAV) endemicity; however, geographical differences exist. We did a systematic review with the aim of describing seroprevalence and susceptibility in the general population or special groups in the EU and EEA. We searched databases and public health national institutes websites for HAV seroprevalence records published between Jan 1, 1975, and June 30, 2014, with no language restrictions. An updated search was done on Aug 10, 2016. We defined seroprevalence profiles (very low, low, and intermediate) as the proportion of the population with age-specific anti-HAV antibodies at age 15 and 30 years, and susceptibility profiles (low, moderate, high, and very high) as the proportion of susceptible individuals at age 30 and 50 years. We included 228 studies from 28 of 31 EU and EEA countries. For the period 2000–14, 24 countries had a very low seroprevalence profile, compared with five in 1975–89. The susceptibility among adults ranged between low and very high and had a geographical gradient, with three countries in the low susceptibility category. Since 1975, EU and EEA countries have shown decreasing seropositivity; however, considerable regional variability exists. The main limitations of this study are that the studies retrieved for analysis might not be representative of all EU and EEA publications about HAV and might have poor national representativeness. A large proportion of EU and EEA residents are now susceptible to HAV infection. Our Review supports the need to reconsider specific prevention and control measures, to further decrease HAV circulation while providing protection against the infection in the EU and EEA, and could be used to inform susceptible travellers visiting EU and EEA countries with different HAV endemicity levels. Tavoschi, Lara oth Severi, Ettore oth Bonfigli, Sandro oth Edelstein, Michael oth Byström, Emma oth Lopalco, Pierluigi oth Alfonsi, Valeria oth Chilbek, Roman oth Dominguez, Angela oth Galanakis, Emmanouil oth Janta, Denisa oth Kojouharova, Mira oth Ott, Jördis J oth Nelson, Noele oth Papaevangelou, Vassiliki oth Shouval, Daniel oth Uhnoo, Ingrid oth Usonis, Vytautas oth Enthalten in Elsevier Berhane, S. ELSEVIER Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model 2016 New York, NY (DE-627)ELV013808834 volume:17 year:2017 number:10 pages:306-319 extent:14 https://doi.org/10.1016/S1473-3099(17)30392-4 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_26 GBV_ILN_40 GBV_ILN_70 44.44 Parasitologie Medizin VZ AR 17 2017 10 306-319 14 17.2017, 10, e306-, (14 S.) 045F 610 |
| allfields_unstemmed |
10.1016/S1473-3099(17)30392-4 doi GBV00000000000044A.pica (DE-627)ELV030304091 (ELSEVIER)S1473-3099(17)30392-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl Carrillo-Santisteve, Paloma verfasserin aut Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: a systematic review 2017transfer abstract 14 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Most of the European Union (EU) and European Economic Area (EEA) is considered a region of very low hepatitis A virus (HAV) endemicity; however, geographical differences exist. We did a systematic review with the aim of describing seroprevalence and susceptibility in the general population or special groups in the EU and EEA. We searched databases and public health national institutes websites for HAV seroprevalence records published between Jan 1, 1975, and June 30, 2014, with no language restrictions. An updated search was done on Aug 10, 2016. We defined seroprevalence profiles (very low, low, and intermediate) as the proportion of the population with age-specific anti-HAV antibodies at age 15 and 30 years, and susceptibility profiles (low, moderate, high, and very high) as the proportion of susceptible individuals at age 30 and 50 years. We included 228 studies from 28 of 31 EU and EEA countries. For the period 2000–14, 24 countries had a very low seroprevalence profile, compared with five in 1975–89. The susceptibility among adults ranged between low and very high and had a geographical gradient, with three countries in the low susceptibility category. Since 1975, EU and EEA countries have shown decreasing seropositivity; however, considerable regional variability exists. The main limitations of this study are that the studies retrieved for analysis might not be representative of all EU and EEA publications about HAV and might have poor national representativeness. A large proportion of EU and EEA residents are now susceptible to HAV infection. Our Review supports the need to reconsider specific prevention and control measures, to further decrease HAV circulation while providing protection against the infection in the EU and EEA, and could be used to inform susceptible travellers visiting EU and EEA countries with different HAV endemicity levels. Most of the European Union (EU) and European Economic Area (EEA) is considered a region of very low hepatitis A virus (HAV) endemicity; however, geographical differences exist. We did a systematic review with the aim of describing seroprevalence and susceptibility in the general population or special groups in the EU and EEA. We searched databases and public health national institutes websites for HAV seroprevalence records published between Jan 1, 1975, and June 30, 2014, with no language restrictions. An updated search was done on Aug 10, 2016. We defined seroprevalence profiles (very low, low, and intermediate) as the proportion of the population with age-specific anti-HAV antibodies at age 15 and 30 years, and susceptibility profiles (low, moderate, high, and very high) as the proportion of susceptible individuals at age 30 and 50 years. We included 228 studies from 28 of 31 EU and EEA countries. For the period 2000–14, 24 countries had a very low seroprevalence profile, compared with five in 1975–89. The susceptibility among adults ranged between low and very high and had a geographical gradient, with three countries in the low susceptibility category. Since 1975, EU and EEA countries have shown decreasing seropositivity; however, considerable regional variability exists. The main limitations of this study are that the studies retrieved for analysis might not be representative of all EU and EEA publications about HAV and might have poor national representativeness. A large proportion of EU and EEA residents are now susceptible to HAV infection. Our Review supports the need to reconsider specific prevention and control measures, to further decrease HAV circulation while providing protection against the infection in the EU and EEA, and could be used to inform susceptible travellers visiting EU and EEA countries with different HAV endemicity levels. Tavoschi, Lara oth Severi, Ettore oth Bonfigli, Sandro oth Edelstein, Michael oth Byström, Emma oth Lopalco, Pierluigi oth Alfonsi, Valeria oth Chilbek, Roman oth Dominguez, Angela oth Galanakis, Emmanouil oth Janta, Denisa oth Kojouharova, Mira oth Ott, Jördis J oth Nelson, Noele oth Papaevangelou, Vassiliki oth Shouval, Daniel oth Uhnoo, Ingrid oth Usonis, Vytautas oth Enthalten in Elsevier Berhane, S. ELSEVIER Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model 2016 New York, NY (DE-627)ELV013808834 volume:17 year:2017 number:10 pages:306-319 extent:14 https://doi.org/10.1016/S1473-3099(17)30392-4 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_26 GBV_ILN_40 GBV_ILN_70 44.44 Parasitologie Medizin VZ AR 17 2017 10 306-319 14 17.2017, 10, e306-, (14 S.) 045F 610 |
| allfieldsGer |
10.1016/S1473-3099(17)30392-4 doi GBV00000000000044A.pica (DE-627)ELV030304091 (ELSEVIER)S1473-3099(17)30392-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl Carrillo-Santisteve, Paloma verfasserin aut Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: a systematic review 2017transfer abstract 14 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Most of the European Union (EU) and European Economic Area (EEA) is considered a region of very low hepatitis A virus (HAV) endemicity; however, geographical differences exist. We did a systematic review with the aim of describing seroprevalence and susceptibility in the general population or special groups in the EU and EEA. We searched databases and public health national institutes websites for HAV seroprevalence records published between Jan 1, 1975, and June 30, 2014, with no language restrictions. An updated search was done on Aug 10, 2016. We defined seroprevalence profiles (very low, low, and intermediate) as the proportion of the population with age-specific anti-HAV antibodies at age 15 and 30 years, and susceptibility profiles (low, moderate, high, and very high) as the proportion of susceptible individuals at age 30 and 50 years. We included 228 studies from 28 of 31 EU and EEA countries. For the period 2000–14, 24 countries had a very low seroprevalence profile, compared with five in 1975–89. The susceptibility among adults ranged between low and very high and had a geographical gradient, with three countries in the low susceptibility category. Since 1975, EU and EEA countries have shown decreasing seropositivity; however, considerable regional variability exists. The main limitations of this study are that the studies retrieved for analysis might not be representative of all EU and EEA publications about HAV and might have poor national representativeness. A large proportion of EU and EEA residents are now susceptible to HAV infection. Our Review supports the need to reconsider specific prevention and control measures, to further decrease HAV circulation while providing protection against the infection in the EU and EEA, and could be used to inform susceptible travellers visiting EU and EEA countries with different HAV endemicity levels. Most of the European Union (EU) and European Economic Area (EEA) is considered a region of very low hepatitis A virus (HAV) endemicity; however, geographical differences exist. We did a systematic review with the aim of describing seroprevalence and susceptibility in the general population or special groups in the EU and EEA. We searched databases and public health national institutes websites for HAV seroprevalence records published between Jan 1, 1975, and June 30, 2014, with no language restrictions. An updated search was done on Aug 10, 2016. We defined seroprevalence profiles (very low, low, and intermediate) as the proportion of the population with age-specific anti-HAV antibodies at age 15 and 30 years, and susceptibility profiles (low, moderate, high, and very high) as the proportion of susceptible individuals at age 30 and 50 years. We included 228 studies from 28 of 31 EU and EEA countries. For the period 2000–14, 24 countries had a very low seroprevalence profile, compared with five in 1975–89. The susceptibility among adults ranged between low and very high and had a geographical gradient, with three countries in the low susceptibility category. Since 1975, EU and EEA countries have shown decreasing seropositivity; however, considerable regional variability exists. The main limitations of this study are that the studies retrieved for analysis might not be representative of all EU and EEA publications about HAV and might have poor national representativeness. A large proportion of EU and EEA residents are now susceptible to HAV infection. Our Review supports the need to reconsider specific prevention and control measures, to further decrease HAV circulation while providing protection against the infection in the EU and EEA, and could be used to inform susceptible travellers visiting EU and EEA countries with different HAV endemicity levels. Tavoschi, Lara oth Severi, Ettore oth Bonfigli, Sandro oth Edelstein, Michael oth Byström, Emma oth Lopalco, Pierluigi oth Alfonsi, Valeria oth Chilbek, Roman oth Dominguez, Angela oth Galanakis, Emmanouil oth Janta, Denisa oth Kojouharova, Mira oth Ott, Jördis J oth Nelson, Noele oth Papaevangelou, Vassiliki oth Shouval, Daniel oth Uhnoo, Ingrid oth Usonis, Vytautas oth Enthalten in Elsevier Berhane, S. ELSEVIER Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model 2016 New York, NY (DE-627)ELV013808834 volume:17 year:2017 number:10 pages:306-319 extent:14 https://doi.org/10.1016/S1473-3099(17)30392-4 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_26 GBV_ILN_40 GBV_ILN_70 44.44 Parasitologie Medizin VZ AR 17 2017 10 306-319 14 17.2017, 10, e306-, (14 S.) 045F 610 |
| allfieldsSound |
10.1016/S1473-3099(17)30392-4 doi GBV00000000000044A.pica (DE-627)ELV030304091 (ELSEVIER)S1473-3099(17)30392-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl Carrillo-Santisteve, Paloma verfasserin aut Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: a systematic review 2017transfer abstract 14 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Most of the European Union (EU) and European Economic Area (EEA) is considered a region of very low hepatitis A virus (HAV) endemicity; however, geographical differences exist. We did a systematic review with the aim of describing seroprevalence and susceptibility in the general population or special groups in the EU and EEA. We searched databases and public health national institutes websites for HAV seroprevalence records published between Jan 1, 1975, and June 30, 2014, with no language restrictions. An updated search was done on Aug 10, 2016. We defined seroprevalence profiles (very low, low, and intermediate) as the proportion of the population with age-specific anti-HAV antibodies at age 15 and 30 years, and susceptibility profiles (low, moderate, high, and very high) as the proportion of susceptible individuals at age 30 and 50 years. We included 228 studies from 28 of 31 EU and EEA countries. For the period 2000–14, 24 countries had a very low seroprevalence profile, compared with five in 1975–89. The susceptibility among adults ranged between low and very high and had a geographical gradient, with three countries in the low susceptibility category. Since 1975, EU and EEA countries have shown decreasing seropositivity; however, considerable regional variability exists. The main limitations of this study are that the studies retrieved for analysis might not be representative of all EU and EEA publications about HAV and might have poor national representativeness. A large proportion of EU and EEA residents are now susceptible to HAV infection. Our Review supports the need to reconsider specific prevention and control measures, to further decrease HAV circulation while providing protection against the infection in the EU and EEA, and could be used to inform susceptible travellers visiting EU and EEA countries with different HAV endemicity levels. Most of the European Union (EU) and European Economic Area (EEA) is considered a region of very low hepatitis A virus (HAV) endemicity; however, geographical differences exist. We did a systematic review with the aim of describing seroprevalence and susceptibility in the general population or special groups in the EU and EEA. We searched databases and public health national institutes websites for HAV seroprevalence records published between Jan 1, 1975, and June 30, 2014, with no language restrictions. An updated search was done on Aug 10, 2016. We defined seroprevalence profiles (very low, low, and intermediate) as the proportion of the population with age-specific anti-HAV antibodies at age 15 and 30 years, and susceptibility profiles (low, moderate, high, and very high) as the proportion of susceptible individuals at age 30 and 50 years. We included 228 studies from 28 of 31 EU and EEA countries. For the period 2000–14, 24 countries had a very low seroprevalence profile, compared with five in 1975–89. The susceptibility among adults ranged between low and very high and had a geographical gradient, with three countries in the low susceptibility category. Since 1975, EU and EEA countries have shown decreasing seropositivity; however, considerable regional variability exists. The main limitations of this study are that the studies retrieved for analysis might not be representative of all EU and EEA publications about HAV and might have poor national representativeness. A large proportion of EU and EEA residents are now susceptible to HAV infection. Our Review supports the need to reconsider specific prevention and control measures, to further decrease HAV circulation while providing protection against the infection in the EU and EEA, and could be used to inform susceptible travellers visiting EU and EEA countries with different HAV endemicity levels. Tavoschi, Lara oth Severi, Ettore oth Bonfigli, Sandro oth Edelstein, Michael oth Byström, Emma oth Lopalco, Pierluigi oth Alfonsi, Valeria oth Chilbek, Roman oth Dominguez, Angela oth Galanakis, Emmanouil oth Janta, Denisa oth Kojouharova, Mira oth Ott, Jördis J oth Nelson, Noele oth Papaevangelou, Vassiliki oth Shouval, Daniel oth Uhnoo, Ingrid oth Usonis, Vytautas oth Enthalten in Elsevier Berhane, S. ELSEVIER Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model 2016 New York, NY (DE-627)ELV013808834 volume:17 year:2017 number:10 pages:306-319 extent:14 https://doi.org/10.1016/S1473-3099(17)30392-4 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_26 GBV_ILN_40 GBV_ILN_70 44.44 Parasitologie Medizin VZ AR 17 2017 10 306-319 14 17.2017, 10, e306-, (14 S.) 045F 610 |
| language |
English |
| source |
Enthalten in Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model New York, NY volume:17 year:2017 number:10 pages:306-319 extent:14 |
| sourceStr |
Enthalten in Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model New York, NY volume:17 year:2017 number:10 pages:306-319 extent:14 |
| format_phy_str_mv |
Article |
| bklname |
Parasitologie |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model |
| authorswithroles_txt_mv |
Carrillo-Santisteve, Paloma @@aut@@ Tavoschi, Lara @@oth@@ Severi, Ettore @@oth@@ Bonfigli, Sandro @@oth@@ Edelstein, Michael @@oth@@ Byström, Emma @@oth@@ Lopalco, Pierluigi @@oth@@ Alfonsi, Valeria @@oth@@ Chilbek, Roman @@oth@@ Dominguez, Angela @@oth@@ Galanakis, Emmanouil @@oth@@ Janta, Denisa @@oth@@ Kojouharova, Mira @@oth@@ Ott, Jördis J @@oth@@ Nelson, Noele @@oth@@ Papaevangelou, Vassiliki @@oth@@ Shouval, Daniel @@oth@@ Uhnoo, Ingrid @@oth@@ Usonis, Vytautas @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV013808834 |
| dewey-sort |
3610 |
| id |
ELV030304091 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV030304091</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625181314.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1473-3099(17)30392-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000044A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV030304091</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1473-3099(17)30392-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Carrillo-Santisteve, Paloma</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: a systematic review</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">14</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Most of the European Union (EU) and European Economic Area (EEA) is considered a region of very low hepatitis A virus (HAV) endemicity; however, geographical differences exist. We did a systematic review with the aim of describing seroprevalence and susceptibility in the general population or special groups in the EU and EEA. We searched databases and public health national institutes websites for HAV seroprevalence records published between Jan 1, 1975, and June 30, 2014, with no language restrictions. An updated search was done on Aug 10, 2016. We defined seroprevalence profiles (very low, low, and intermediate) as the proportion of the population with age-specific anti-HAV antibodies at age 15 and 30 years, and susceptibility profiles (low, moderate, high, and very high) as the proportion of susceptible individuals at age 30 and 50 years. We included 228 studies from 28 of 31 EU and EEA countries. For the period 2000–14, 24 countries had a very low seroprevalence profile, compared with five in 1975–89. The susceptibility among adults ranged between low and very high and had a geographical gradient, with three countries in the low susceptibility category. Since 1975, EU and EEA countries have shown decreasing seropositivity; however, considerable regional variability exists. The main limitations of this study are that the studies retrieved for analysis might not be representative of all EU and EEA publications about HAV and might have poor national representativeness. A large proportion of EU and EEA residents are now susceptible to HAV infection. Our Review supports the need to reconsider specific prevention and control measures, to further decrease HAV circulation while providing protection against the infection in the EU and EEA, and could be used to inform susceptible travellers visiting EU and EEA countries with different HAV endemicity levels.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Most of the European Union (EU) and European Economic Area (EEA) is considered a region of very low hepatitis A virus (HAV) endemicity; however, geographical differences exist. We did a systematic review with the aim of describing seroprevalence and susceptibility in the general population or special groups in the EU and EEA. We searched databases and public health national institutes websites for HAV seroprevalence records published between Jan 1, 1975, and June 30, 2014, with no language restrictions. An updated search was done on Aug 10, 2016. We defined seroprevalence profiles (very low, low, and intermediate) as the proportion of the population with age-specific anti-HAV antibodies at age 15 and 30 years, and susceptibility profiles (low, moderate, high, and very high) as the proportion of susceptible individuals at age 30 and 50 years. We included 228 studies from 28 of 31 EU and EEA countries. For the period 2000–14, 24 countries had a very low seroprevalence profile, compared with five in 1975–89. The susceptibility among adults ranged between low and very high and had a geographical gradient, with three countries in the low susceptibility category. Since 1975, EU and EEA countries have shown decreasing seropositivity; however, considerable regional variability exists. The main limitations of this study are that the studies retrieved for analysis might not be representative of all EU and EEA publications about HAV and might have poor national representativeness. A large proportion of EU and EEA residents are now susceptible to HAV infection. Our Review supports the need to reconsider specific prevention and control measures, to further decrease HAV circulation while providing protection against the infection in the EU and EEA, and could be used to inform susceptible travellers visiting EU and EEA countries with different HAV endemicity levels.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tavoschi, Lara</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Severi, Ettore</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bonfigli, Sandro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Edelstein, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Byström, Emma</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lopalco, Pierluigi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alfonsi, Valeria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chilbek, Roman</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dominguez, Angela</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Galanakis, Emmanouil</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Janta, Denisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kojouharova, Mira</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ott, Jördis J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nelson, Noele</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Papaevangelou, Vassiliki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shouval, Daniel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Uhnoo, Ingrid</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Usonis, Vytautas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Berhane, S. ELSEVIER</subfield><subfield code="t">Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model</subfield><subfield code="d">2016</subfield><subfield code="g">New York, NY</subfield><subfield code="w">(DE-627)ELV013808834</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:10</subfield><subfield code="g">pages:306-319</subfield><subfield code="g">extent:14</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1473-3099(17)30392-4</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_26</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">2017</subfield><subfield code="e">10</subfield><subfield code="h">306-319</subfield><subfield code="g">14</subfield><subfield code="y">17.2017, 10, e306-, (14 S.)</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Carrillo-Santisteve, Paloma |
| spellingShingle |
Carrillo-Santisteve, Paloma ddc 610 bkl 44.44 Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: a systematic review |
| authorStr |
Carrillo-Santisteve, Paloma |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV013808834 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.44 bkl Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: a systematic review |
| topic |
ddc 610 bkl 44.44 |
| topic_unstemmed |
ddc 610 bkl 44.44 |
| topic_browse |
ddc 610 bkl 44.44 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
l t lt e s es s b sb m e me e b eb p l pl v a va r c rc a d ad e g eg d j dj m k mk j j o jj jjo n n nn v p vp d s ds i u iu v u vu |
| hierarchy_parent_title |
Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model |
| hierarchy_parent_id |
ELV013808834 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV013808834 |
| title |
Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: a systematic review |
| ctrlnum |
(DE-627)ELV030304091 (ELSEVIER)S1473-3099(17)30392-4 |
| title_full |
Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: a systematic review |
| author_sort |
Carrillo-Santisteve, Paloma |
| journal |
Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model |
| journalStr |
Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
306 |
| author_browse |
Carrillo-Santisteve, Paloma |
| container_volume |
17 |
| physical |
14 |
| class |
610 610 DE-600 610 VZ 44.44 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Carrillo-Santisteve, Paloma |
| doi_str_mv |
10.1016/S1473-3099(17)30392-4 |
| dewey-full |
610 |
| title_sort |
seroprevalence and susceptibility to hepatitis a in the european union and european economic area: a systematic review |
| title_auth |
Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: a systematic review |
| abstract |
Most of the European Union (EU) and European Economic Area (EEA) is considered a region of very low hepatitis A virus (HAV) endemicity; however, geographical differences exist. We did a systematic review with the aim of describing seroprevalence and susceptibility in the general population or special groups in the EU and EEA. We searched databases and public health national institutes websites for HAV seroprevalence records published between Jan 1, 1975, and June 30, 2014, with no language restrictions. An updated search was done on Aug 10, 2016. We defined seroprevalence profiles (very low, low, and intermediate) as the proportion of the population with age-specific anti-HAV antibodies at age 15 and 30 years, and susceptibility profiles (low, moderate, high, and very high) as the proportion of susceptible individuals at age 30 and 50 years. We included 228 studies from 28 of 31 EU and EEA countries. For the period 2000–14, 24 countries had a very low seroprevalence profile, compared with five in 1975–89. The susceptibility among adults ranged between low and very high and had a geographical gradient, with three countries in the low susceptibility category. Since 1975, EU and EEA countries have shown decreasing seropositivity; however, considerable regional variability exists. The main limitations of this study are that the studies retrieved for analysis might not be representative of all EU and EEA publications about HAV and might have poor national representativeness. A large proportion of EU and EEA residents are now susceptible to HAV infection. Our Review supports the need to reconsider specific prevention and control measures, to further decrease HAV circulation while providing protection against the infection in the EU and EEA, and could be used to inform susceptible travellers visiting EU and EEA countries with different HAV endemicity levels. |
| abstractGer |
Most of the European Union (EU) and European Economic Area (EEA) is considered a region of very low hepatitis A virus (HAV) endemicity; however, geographical differences exist. We did a systematic review with the aim of describing seroprevalence and susceptibility in the general population or special groups in the EU and EEA. We searched databases and public health national institutes websites for HAV seroprevalence records published between Jan 1, 1975, and June 30, 2014, with no language restrictions. An updated search was done on Aug 10, 2016. We defined seroprevalence profiles (very low, low, and intermediate) as the proportion of the population with age-specific anti-HAV antibodies at age 15 and 30 years, and susceptibility profiles (low, moderate, high, and very high) as the proportion of susceptible individuals at age 30 and 50 years. We included 228 studies from 28 of 31 EU and EEA countries. For the period 2000–14, 24 countries had a very low seroprevalence profile, compared with five in 1975–89. The susceptibility among adults ranged between low and very high and had a geographical gradient, with three countries in the low susceptibility category. Since 1975, EU and EEA countries have shown decreasing seropositivity; however, considerable regional variability exists. The main limitations of this study are that the studies retrieved for analysis might not be representative of all EU and EEA publications about HAV and might have poor national representativeness. A large proportion of EU and EEA residents are now susceptible to HAV infection. Our Review supports the need to reconsider specific prevention and control measures, to further decrease HAV circulation while providing protection against the infection in the EU and EEA, and could be used to inform susceptible travellers visiting EU and EEA countries with different HAV endemicity levels. |
| abstract_unstemmed |
Most of the European Union (EU) and European Economic Area (EEA) is considered a region of very low hepatitis A virus (HAV) endemicity; however, geographical differences exist. We did a systematic review with the aim of describing seroprevalence and susceptibility in the general population or special groups in the EU and EEA. We searched databases and public health national institutes websites for HAV seroprevalence records published between Jan 1, 1975, and June 30, 2014, with no language restrictions. An updated search was done on Aug 10, 2016. We defined seroprevalence profiles (very low, low, and intermediate) as the proportion of the population with age-specific anti-HAV antibodies at age 15 and 30 years, and susceptibility profiles (low, moderate, high, and very high) as the proportion of susceptible individuals at age 30 and 50 years. We included 228 studies from 28 of 31 EU and EEA countries. For the period 2000–14, 24 countries had a very low seroprevalence profile, compared with five in 1975–89. The susceptibility among adults ranged between low and very high and had a geographical gradient, with three countries in the low susceptibility category. Since 1975, EU and EEA countries have shown decreasing seropositivity; however, considerable regional variability exists. The main limitations of this study are that the studies retrieved for analysis might not be representative of all EU and EEA publications about HAV and might have poor national representativeness. A large proportion of EU and EEA residents are now susceptible to HAV infection. Our Review supports the need to reconsider specific prevention and control measures, to further decrease HAV circulation while providing protection against the infection in the EU and EEA, and could be used to inform susceptible travellers visiting EU and EEA countries with different HAV endemicity levels. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_26 GBV_ILN_40 GBV_ILN_70 |
| container_issue |
10 |
| title_short |
Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: a systematic review |
| url |
https://doi.org/10.1016/S1473-3099(17)30392-4 |
| remote_bool |
true |
| author2 |
Tavoschi, Lara Severi, Ettore Bonfigli, Sandro Edelstein, Michael Byström, Emma Lopalco, Pierluigi Alfonsi, Valeria Chilbek, Roman Dominguez, Angela Galanakis, Emmanouil Janta, Denisa Kojouharova, Mira Ott, Jördis J Nelson, Noele Papaevangelou, Vassiliki Shouval, Daniel Uhnoo, Ingrid Usonis, Vytautas |
| author2Str |
Tavoschi, Lara Severi, Ettore Bonfigli, Sandro Edelstein, Michael Byström, Emma Lopalco, Pierluigi Alfonsi, Valeria Chilbek, Roman Dominguez, Angela Galanakis, Emmanouil Janta, Denisa Kojouharova, Mira Ott, Jördis J Nelson, Noele Papaevangelou, Vassiliki Shouval, Daniel Uhnoo, Ingrid Usonis, Vytautas |
| ppnlink |
ELV013808834 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/S1473-3099(17)30392-4 |
| up_date |
2024-07-06T17:14:10.727Z |
| _version_ |
1803850665928163328 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV030304091</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625181314.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1473-3099(17)30392-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000044A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV030304091</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1473-3099(17)30392-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Carrillo-Santisteve, Paloma</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: a systematic review</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">14</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Most of the European Union (EU) and European Economic Area (EEA) is considered a region of very low hepatitis A virus (HAV) endemicity; however, geographical differences exist. We did a systematic review with the aim of describing seroprevalence and susceptibility in the general population or special groups in the EU and EEA. We searched databases and public health national institutes websites for HAV seroprevalence records published between Jan 1, 1975, and June 30, 2014, with no language restrictions. An updated search was done on Aug 10, 2016. We defined seroprevalence profiles (very low, low, and intermediate) as the proportion of the population with age-specific anti-HAV antibodies at age 15 and 30 years, and susceptibility profiles (low, moderate, high, and very high) as the proportion of susceptible individuals at age 30 and 50 years. We included 228 studies from 28 of 31 EU and EEA countries. For the period 2000–14, 24 countries had a very low seroprevalence profile, compared with five in 1975–89. The susceptibility among adults ranged between low and very high and had a geographical gradient, with three countries in the low susceptibility category. Since 1975, EU and EEA countries have shown decreasing seropositivity; however, considerable regional variability exists. The main limitations of this study are that the studies retrieved for analysis might not be representative of all EU and EEA publications about HAV and might have poor national representativeness. A large proportion of EU and EEA residents are now susceptible to HAV infection. Our Review supports the need to reconsider specific prevention and control measures, to further decrease HAV circulation while providing protection against the infection in the EU and EEA, and could be used to inform susceptible travellers visiting EU and EEA countries with different HAV endemicity levels.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Most of the European Union (EU) and European Economic Area (EEA) is considered a region of very low hepatitis A virus (HAV) endemicity; however, geographical differences exist. We did a systematic review with the aim of describing seroprevalence and susceptibility in the general population or special groups in the EU and EEA. We searched databases and public health national institutes websites for HAV seroprevalence records published between Jan 1, 1975, and June 30, 2014, with no language restrictions. An updated search was done on Aug 10, 2016. We defined seroprevalence profiles (very low, low, and intermediate) as the proportion of the population with age-specific anti-HAV antibodies at age 15 and 30 years, and susceptibility profiles (low, moderate, high, and very high) as the proportion of susceptible individuals at age 30 and 50 years. We included 228 studies from 28 of 31 EU and EEA countries. For the period 2000–14, 24 countries had a very low seroprevalence profile, compared with five in 1975–89. The susceptibility among adults ranged between low and very high and had a geographical gradient, with three countries in the low susceptibility category. Since 1975, EU and EEA countries have shown decreasing seropositivity; however, considerable regional variability exists. The main limitations of this study are that the studies retrieved for analysis might not be representative of all EU and EEA publications about HAV and might have poor national representativeness. A large proportion of EU and EEA residents are now susceptible to HAV infection. Our Review supports the need to reconsider specific prevention and control measures, to further decrease HAV circulation while providing protection against the infection in the EU and EEA, and could be used to inform susceptible travellers visiting EU and EEA countries with different HAV endemicity levels.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tavoschi, Lara</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Severi, Ettore</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bonfigli, Sandro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Edelstein, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Byström, Emma</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lopalco, Pierluigi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alfonsi, Valeria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chilbek, Roman</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dominguez, Angela</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Galanakis, Emmanouil</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Janta, Denisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kojouharova, Mira</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ott, Jördis J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nelson, Noele</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Papaevangelou, Vassiliki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shouval, Daniel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Uhnoo, Ingrid</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Usonis, Vytautas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Berhane, S. ELSEVIER</subfield><subfield code="t">Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model</subfield><subfield code="d">2016</subfield><subfield code="g">New York, NY</subfield><subfield code="w">(DE-627)ELV013808834</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:10</subfield><subfield code="g">pages:306-319</subfield><subfield code="g">extent:14</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1473-3099(17)30392-4</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_26</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">2017</subfield><subfield code="e">10</subfield><subfield code="h">306-319</subfield><subfield code="g">14</subfield><subfield code="y">17.2017, 10, e306-, (14 S.)</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.3974047 |